Developing safer medicines using deuterium labeling techniques
Highly Selective Cu-Catalyzed Reactions for Precision Deuteration and Alkyne Hydrofunctionalization
['FUNDING_OTHER'] · UNIVERSITY OF TENNESSEE KNOXVILLE · NIH-11204002
This study is exploring new ways to make medications safer and more effective by adding a special form of hydrogen called deuterium to the drug molecules, and it's aimed at helping researchers create better treatments for everyone.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TENNESSEE KNOXVILLE (nih funded) |
| Locations | 1 site (KNOXVILLE, UNITED STATES) |
| Trial ID | NIH-11204002 on ClinicalTrials.gov |
What this research studies
This research focuses on creating safer alternatives to existing medications by incorporating deuterium into drug molecules. The team aims to develop highly selective chemical reactions that allow for precise deuteration, which can enhance the safety and efficacy of drug candidates. By collaborating with experts in spectroscopy, they are also working on improving analytical techniques to accurately characterize these deuterated compounds. The goal is to advance the field of medicinal chemistry by providing better methods for drug development.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals who require new therapeutic options for their conditions.
Not a fit: Patients who are not seeking new treatment options or those with conditions that do not respond to deuterated medicines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the creation of safer and more effective medications for patients.
How similar studies have performed: While the approach of using deuterium in drug development is promising, it is still relatively novel and untested in many applications.
Where this research is happening
KNOXVILLE, UNITED STATES
- UNIVERSITY OF TENNESSEE KNOXVILLE — KNOXVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CLARK, JOSEPH — UNIVERSITY OF TENNESSEE KNOXVILLE
- Study coordinator: CLARK, JOSEPH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.